The cost-effectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risks

Sep-07

Gynecology and Obstetrics Healthcare Cost Musculoskeletal Pharmacoepidemiology Women's Health

AUTHORS : Prof Tjeerd Van Staa (Details for study: Utrecht Institute for Pharmaceutical Sciences), Health e-Research Centre, School of Health Sciences, Faculty of Biology, Medicine and Health, the University of Manchester, Manchester, Oxford Road, Manchester, M13 9PL, UK – Email: tjeerd.vanstaa@manchester.ac.uk – Profile: https://www.research.manchester.ac.uk/portal/tjeerd.vanstaa.html

JOURNAL : Value in Health

REFERENCE: 10(5):348-57

DOI : 10.1111/j.1524-4733.2007.00188.x

The cost-effectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risks

More publications

Comparative effect of aspirin versus clopidogrel monotherapy on incident type 2 diabetes in patients with atherosclerotic cardiovascular diseases: A target trial emulation study

Postoperative Weight Loss After Antiobesity Medications and Revision Risk After Joint Replacement

Comparative effectiveness and prescribing trends of modified release versus immediate release indapamide in patients with hypertension: cohort study